A machine-learning based objective measure for ALS disease severity.
Fernando G Vieira, Subhashini Venugopalan, Alan S Premasiri...
https://pubmed.ncbi.nlm.nih.gov/35396385/Actively Recruiting
Led by ALS Therapy Development Institute · Updated on 2025-03-20
2000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are conducting a natural history study to better understand the biological and clinical aspects of amyotrophic lateral sclerosis ALS and related motor neuron diseases MND. This study aims to support drug discovery, biomarker identification, and validation of outcome measures. Adults living with ALS or MND, those carrying known ALS-related genetic mutations without symptoms, and healthy volunteers participate remotely in this observational research sponsored by the ALS Therapy Development Institute. Participants include adults over 18 years old who fall into one of three groups individuals diagnosed with ALS or MND, adults carrying an ALS-associated mutation without symptoms, and healthy adults with no biological connection to ALS or significant health issues. Data collection involves monthly assessments, surveys, and monitoring over an average period of one year or more, depending on the measure. Throughout the study, participants complete monthly evaluations using tools like the ALS Functional Rating Scale - Revised ALSFRS-R, speech scoring based on machine learning, and limb-based accelerometry. They also fill out surveys about medications, supplements, clinical trial participation, and social or environmental factors at specified intervals. These assessments help researchers track disease progression and gather comprehensive information to advance ALS research and potential treatments.
CONDITIONS
ALS Research Collaborative
A
Alan S Premasiri, M.S.
B
Beth Levine
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
ALS Therapy Development Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Up to 1 year
Participants are monitored through regular assessments including functional rating scales, speech scoring, and surveys to track disease progression and other health factors.
Monthly visits for most assessments; quarterly surveys at months 1, 4, 7, and 10
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Fernando G Vieira, Subhashini Venugopalan, Alan S Premasiri...
https://pubmed.ncbi.nlm.nih.gov/35396385/Anoopum S Gupta, Siddharth Patel, Alan Premasiri...
https://pubmed.ncbi.nlm.nih.gov/37604821/Marcin Straczkiewicz, Katherine M Burke, Narghes Calcagno...
https://pubmed.ncbi.nlm.nih.gov/39707523/ALS Therapy Development Institute
Lead Sponsor